Binhui Biopharmaceutical and Canada's TheraPten BioSciences Inc signed cooperation agreement on the development of HSV2-based oncolytic virus expressing the cell penetrating tumor suppressor gene PTEN (including PTEN-L). TheraPten is a Canadian biotech company that advocates "put the cell-permeable tumor suppressors back to cancer patients who have lost". PTEN-L is a newly discovered tumor suppressor protein, which plays a key role in regulating the tumor immunology. One report published in Nature Communications on Nov 27, 2018 showed that macrophages were activated after PTEN-L expressed in the brain of mice with glioblastoma; PTEN-L could also activate CD8(+) T cells and natural killer cells; PTEN-L could also reduce the expression of PD-L1 on the cell surface. Highly expression of PTEN-L tumor suppressor protein in tumor cells by oncolytic virus can eliminate mouse brain tumors (glioblastoma). PTEN protein is completely lost in at least 30% of cancer patients in the world, regardless of cancer stages or indications,. The loss of PTEN is closely related to the progression of cancer (main cause of tumor progression). In fact, the absence of PTEN confers the resistance to more than 30 FDA-approved drugs, including immuno-oncology (checkpoint) antibodies. Therefore, the re-introduction of cell-permeable PTEN tumor suppressor factor directly (in the form of purified protein) or through Binhui's oHSV2 platform in cancer patients is expected to have a profound impact on cancer treatment.